Format

Send to

Choose Destination
J Am Acad Dermatol. 1994 Oct;31(4):617-9.

Interferon therapy for Behçet's disease.

Author information

1
Department of Dermatology, Akdeniz University Medical Faculty, Antalya, Turkey.

Abstract

BACKGROUND:

Behçet's disease was first described in 1937 as a trisymptom complex. No standard therapy has been established. Its cause is presumed to be viral or immunologic.

OBJECTIVE:

We sought to determine whether patients with Behçet's disease benefit from interferon, which has antiviral, immunomodulatory, antiproliferative, and antitumoral properties.

METHODS:

Fourteen patients were initially given 3 MU interferon alfa-2a subcutaneously three times per week. The doses were gradually increased to 12 MU. Each patient received a total dose of 216 MU during the 2-month study. Therapy with 9 MU interferon alfa-2a once a month was continued in half the patients. All patients were observed before and after treatment for 6-month periods, and all symptoms were recorded.

RESULTS:

All patients were symptom free by the end of the 2-month treatment period. The frequencies of oral and genital ulcers as well as pustular vasculitis decreased significantly in the posttreatment period as compared with the pretreatment period.

CONCLUSION:

The data suggest that interferon treatment appears to be effective for patients with Behçet's disease.

PMID:
8089288
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center